Medical treatment of metastatic renal cell carcinoma

U. Tirelli, S. Frustaci, E. Galligioni, A. Veronesi, M. G. Trovò, D. M. Magri, D. Crivellari, M. Roncadin, S. Tumolo, E. Grigoletto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Thirty-five patients with metastatic renal cell carcinoma (RCC) were observed over a 57 month period; 30 these were suitable for analysis. Medroxyprogesterone acetate (MPA) was selected as the primary treatment agent in 23 patients. Vinblastine alone (VLB) or in combination with MPA or other non hormonal agents was used in 1, 4, and 2 patients, respectively. With MPA the treatment response rate was 3 out of 23 patients (1 complete remission and 2 partial responses). The duration of the response for the patient with complete remission was 6 months, whereas the patients with partial response showed a duration of 21 and 14 months, respectively. Four additional patients showed no response. With the VLB-MPA combination the response rate was 1 out of 4 (1 partial remission); the duration of this partial remission was 3 months. The median duration of survival for the 11 patients with complete remission, partial remission and no change was 14 months, whereas for the 19 patients with no response it was 7 months. Testosterone propionate and tamoxifen showed no or minimal effects as secondary treatment agents.

Original languageEnglish
Pages (from-to)235-240
Number of pages6
JournalTumori
Volume66
Issue number2
Publication statusPublished - 1980

Fingerprint

Renal Cell Carcinoma
Medroxyprogesterone Acetate
Therapeutics
Testosterone Propionate
Vinblastine
Tamoxifen
Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

Tirelli, U., Frustaci, S., Galligioni, E., Veronesi, A., Trovò, M. G., Magri, D. M., ... Grigoletto, E. (1980). Medical treatment of metastatic renal cell carcinoma. Tumori, 66(2), 235-240.

Medical treatment of metastatic renal cell carcinoma. / Tirelli, U.; Frustaci, S.; Galligioni, E.; Veronesi, A.; Trovò, M. G.; Magri, D. M.; Crivellari, D.; Roncadin, M.; Tumolo, S.; Grigoletto, E.

In: Tumori, Vol. 66, No. 2, 1980, p. 235-240.

Research output: Contribution to journalArticle

Tirelli, U, Frustaci, S, Galligioni, E, Veronesi, A, Trovò, MG, Magri, DM, Crivellari, D, Roncadin, M, Tumolo, S & Grigoletto, E 1980, 'Medical treatment of metastatic renal cell carcinoma', Tumori, vol. 66, no. 2, pp. 235-240.
Tirelli U, Frustaci S, Galligioni E, Veronesi A, Trovò MG, Magri DM et al. Medical treatment of metastatic renal cell carcinoma. Tumori. 1980;66(2):235-240.
Tirelli, U. ; Frustaci, S. ; Galligioni, E. ; Veronesi, A. ; Trovò, M. G. ; Magri, D. M. ; Crivellari, D. ; Roncadin, M. ; Tumolo, S. ; Grigoletto, E. / Medical treatment of metastatic renal cell carcinoma. In: Tumori. 1980 ; Vol. 66, No. 2. pp. 235-240.
@article{eb915d78bb134ec2a37378f32505b65b,
title = "Medical treatment of metastatic renal cell carcinoma",
abstract = "Thirty-five patients with metastatic renal cell carcinoma (RCC) were observed over a 57 month period; 30 these were suitable for analysis. Medroxyprogesterone acetate (MPA) was selected as the primary treatment agent in 23 patients. Vinblastine alone (VLB) or in combination with MPA or other non hormonal agents was used in 1, 4, and 2 patients, respectively. With MPA the treatment response rate was 3 out of 23 patients (1 complete remission and 2 partial responses). The duration of the response for the patient with complete remission was 6 months, whereas the patients with partial response showed a duration of 21 and 14 months, respectively. Four additional patients showed no response. With the VLB-MPA combination the response rate was 1 out of 4 (1 partial remission); the duration of this partial remission was 3 months. The median duration of survival for the 11 patients with complete remission, partial remission and no change was 14 months, whereas for the 19 patients with no response it was 7 months. Testosterone propionate and tamoxifen showed no or minimal effects as secondary treatment agents.",
author = "U. Tirelli and S. Frustaci and E. Galligioni and A. Veronesi and Trov{\`o}, {M. G.} and Magri, {D. M.} and D. Crivellari and M. Roncadin and S. Tumolo and E. Grigoletto",
year = "1980",
language = "English",
volume = "66",
pages = "235--240",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Medical treatment of metastatic renal cell carcinoma

AU - Tirelli, U.

AU - Frustaci, S.

AU - Galligioni, E.

AU - Veronesi, A.

AU - Trovò, M. G.

AU - Magri, D. M.

AU - Crivellari, D.

AU - Roncadin, M.

AU - Tumolo, S.

AU - Grigoletto, E.

PY - 1980

Y1 - 1980

N2 - Thirty-five patients with metastatic renal cell carcinoma (RCC) were observed over a 57 month period; 30 these were suitable for analysis. Medroxyprogesterone acetate (MPA) was selected as the primary treatment agent in 23 patients. Vinblastine alone (VLB) or in combination with MPA or other non hormonal agents was used in 1, 4, and 2 patients, respectively. With MPA the treatment response rate was 3 out of 23 patients (1 complete remission and 2 partial responses). The duration of the response for the patient with complete remission was 6 months, whereas the patients with partial response showed a duration of 21 and 14 months, respectively. Four additional patients showed no response. With the VLB-MPA combination the response rate was 1 out of 4 (1 partial remission); the duration of this partial remission was 3 months. The median duration of survival for the 11 patients with complete remission, partial remission and no change was 14 months, whereas for the 19 patients with no response it was 7 months. Testosterone propionate and tamoxifen showed no or minimal effects as secondary treatment agents.

AB - Thirty-five patients with metastatic renal cell carcinoma (RCC) were observed over a 57 month period; 30 these were suitable for analysis. Medroxyprogesterone acetate (MPA) was selected as the primary treatment agent in 23 patients. Vinblastine alone (VLB) or in combination with MPA or other non hormonal agents was used in 1, 4, and 2 patients, respectively. With MPA the treatment response rate was 3 out of 23 patients (1 complete remission and 2 partial responses). The duration of the response for the patient with complete remission was 6 months, whereas the patients with partial response showed a duration of 21 and 14 months, respectively. Four additional patients showed no response. With the VLB-MPA combination the response rate was 1 out of 4 (1 partial remission); the duration of this partial remission was 3 months. The median duration of survival for the 11 patients with complete remission, partial remission and no change was 14 months, whereas for the 19 patients with no response it was 7 months. Testosterone propionate and tamoxifen showed no or minimal effects as secondary treatment agents.

UR - http://www.scopus.com/inward/record.url?scp=0019305176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019305176&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 235

EP - 240

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -